EGFR and non-small cell lung carcinoma: These analyses provide evidence of clinical and statistical benefits across multiple outcomes and adjustment methods, of amivantamab in platinum pre-treated patients with advanced NSCLC harboring <i>EGFR</i> Exon20ins.